However, another study analyzing 35 NSCLC patients who received immunotherapy rechallenge from six Japanese institutions did not find a correlation between the efficacy of rechallenge and PD-L1 expression levels (38). The gene discussed is CD274; the disease is non-small cell lung carcinoma.